08.31.26 -- Understanding Modality-Specific Development Challenges

Continuous bioprocessing is revolutionizing manufacturing. Gain expert insights about cutting-edge innovations in monoclonal antibody production that enable scalable solutions for next-gen therapies.

Explore smarter approaches to γδ T cell manufacturing, including scalable expansion, efficient transduction, and streamlined analytics, as well as how to build workflows that support validation.

Whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, discover how the right system can be tailored to meet the needs of each unique biologic.

Microbial expression systems using automated parallel screening can accelerate therapeutic protein development by improving yield and quality from early-stage production.

Read more about the use of transposase/transposon systems in the biotech industry, particularly in the development of stable cell lines for protein manufacturing.

Breakthroughs in CAR T-cell and stem cell therapies depend on mastering cellular collection. Understanding these fundamentals is vital for advancing treatment efficacy and patient outcomes.

Middlesex County, NJ, offers life sciences organizations a deep talent pool, an extensive R&D presence, and dedicated backing by local government investment.

Evaluate the technical suitability and implementation of simultaneous galactosylation and sialylation across early downstream intermediates to streamline routine manufacturing.

See how we have further improved the platform process with the creation of engineered plasmids that afford significantly higher titers and productivity levels compared to standard systems.